谷歌浏览器插件
订阅小程序
在清言上使用
VIPCreated with Sketch.

Correction To: Can We Accurately Predict Cost Effectiveness Without Access to Overall Survival Data? the Case Study of Nivolumab in Combination with Ipilimumab for the Treatment of Patients with Advanced Melanoma in England

D. Lee,A. Amadi,J. Sabater,J. Ellis,H. Johnson,S. Kotapati,S. McNamara, A. Walker,M. Cooper,K. Patterson,N. Roskell,Y. Meng

PharmacoEconomics - open（2018）

引用 2|浏览0
暂无评分
摘要
The second Key Point for Decision Makers, which reads:
更多
查看译文
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要